StockData
Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc. (CAPR) stock

CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$8.03−0.38 (-4.52%)

Close on Nov 18, 2026Market cap $466.86MP/E –Yield –

Capricor Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Capricor Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$114.90M. For fiscal 2025 it was -$72.72M. The highest annual figure on record is $2.92M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$72.72M–
FY2024Dec 31, 2024-$41.16M–
FY2023Dec 31, 2023-$26.91M-1022.7%
FY2022Dec 31, 2022$2.92M–
FY2021Dec 31, 2021-$18.01M–
FY2020Dec 31, 2020-$10.60M–
FY2019Dec 31, 2019-$6.82M–
FY2018Dec 31, 2018-$14.18M–
FY2017Dec 31, 2017-$14.26M–
FY2016Dec 31, 2016-$14.65M–
FY2015Dec 31, 2015-$10.95M-1475.5%
FY2014Dec 31, 2014$795.88K–
FY2013Dec 31, 2013-$6.20M–
FY2012Dec 31, 2012-$2.08M–
FY2011Dec 31, 2011-$4.65M–
FY2010Dec 31, 2010-$4.32M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$35.55M–
Q1 FY2026Mar 31, 2026-$34.38M–
Q4 FY2025Dec 31, 2025-$25.23M–
Q3 FY2025Sep 30, 2025-$19.74M–
Q2 FY2025Jun 30, 2025-$20.41M–
Q1 FY2025Mar 31, 2025-$7.33M–
Q4 FY2024Dec 31, 2024-$15.29M–
Q3 FY2024Sep 30, 2024-$11.65M–
Q2 FY2024Jun 30, 2024-$12.35M–
Q1 FY2024Mar 31, 2024-$1.88M-148.6%
Q4 FY2023Dec 31, 2023-$12.15M–
Q3 FY2023Sep 30, 2023-$9.06M–
Q2 FY2023Jun 30, 2023-$9.55M–
Q1 FY2023Mar 31, 2023$3.86M-83.5%
Q4 FY2022Dec 31, 2022-$7.60M–
Q3 FY2022Sep 30, 2022-$6.24M–
Q2 FY2022Jun 30, 2022-$6.72M–
Q1 FY2022Mar 31, 2022$23.48M–
Q4 FY2021Dec 31, 2021-$6.00M–
Q3 FY2021Sep 30, 2021-$3.81M–
Q2 FY2021Jun 30, 2021-$4.84M–
Q1 FY2021Mar 31, 2021-$3.37M–
Q4 FY2020Dec 31, 2020-$4.13M–
Q3 FY2020Sep 30, 2020-$3.13M–
Q2 FY2020Jun 30, 2020-$2.12M–
Q1 FY2020Mar 31, 2020-$1.22M–
Q4 FY2019Dec 31, 2019-$1.79M–
Q3 FY2019Sep 30, 2019-$1.65M–
Q2 FY2019Jun 30, 2019-$1.78M–
Q1 FY2019Mar 31, 2019-$1.61M–
Q4 FY2018Dec 31, 2018-$3.76M–
Q3 FY2018Sep 30, 2018-$3.13M–
Q2 FY2018Jun 30, 2018-$3.69M–
Q1 FY2018Mar 31, 2018-$3.60M–
Q4 FY2017Dec 31, 2017-$2.67M–
Q3 FY2017Sep 30, 2017-$3.21M–
Q2 FY2017Jun 30, 2017-$3.71M–
Q1 FY2017Mar 31, 2017-$4.68M–
Q4 FY2016Dec 31, 2016-$3.58M–
Q3 FY2016Sep 30, 2016-$1.92M–

More Capricor Therapeutics figures

See a number that looks wrong?